Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of ...
TipRanks on MSN

Takeda presents interim data from Phase 1b study of mezagitamab

Takeda (TAK) announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab, an anti-CD38 monoclonal ...
YouTube on MSN

Deadlocked REMAKE - Geometry Dash 2.2 #shorts #gd #deluxe12

Deluxe12dd Twitter - X <a href=" Instagram <a href=" Twitch! <a href=" My server Discord! <a href=" My Music! Yt channel: <a ...

GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Systemic Cancer Immunotherapy, at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GEN2 was evaluated in adult patients with advanced solid tumors in an intravenous dose escalation Phase 1 study GEN2 is well-tolerated, with no ...
The Herald Bulletin

State approves Anderson's water rate increase

The city of Anderson has received approval to raise water rates to fund a planned $130 million expansion of its water system.